We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
HaemaLogiX Pty Ltd, a clinical stage biotech company developing novel immuno-oncology and immune therapies for patients with blood cancers, is pleased to both announce the close of a fully subscribed $10 million placement...
The National Comprehensive Cancer Network® (NCCN®) has announced this year's NCCN Annual Congress: Hematologic Malignancies™ will be fully online and open to all attendees at no cost.
Nordic Nanovector CEO Luigi Costa indicated that the company, which is developing new ways to treat blood cancers, has seen increasing interest from potential buyers, as reported in NASDAQ.